Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allurion Technologies, Inc. (NYSE: ALUR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Allurion’s medical device business focused on metabolically healthy weight loss, its Allurion Program, and the Allurion Smart Capsule, which the company describes as a swallowable, Procedureless™ gastric balloon for weight loss and an investigational device in the United States.
Through periodic reports and current reports on Form 8-K, Allurion outlines financial results, capital structure changes, and governance matters. Filings referenced in recent disclosures include notifications of late filing on Form 12b-25, restatements related to accounting for a revenue interest financing agreement and convertible senior secured notes, and descriptions of material weaknesses in internal control over financial reporting. Investors can review these filings to understand how non-cash accounting adjustments affect items such as Other Comprehensive Income (Loss) and Other Income (Expense), as well as the company’s commentary that these corrections are not expected to impact revenue, gross margin, operating expenses, or cash.
Allurion’s SEC filings also describe capital markets and financing transactions, such as a private placement of common stock and accompanying warrants, and an exchange agreement to convert outstanding debt and obligations under revenue interest financing agreements into shares of Series B convertible preferred stock, subject to stockholder approval and exchange listing requirements. Definitive proxy materials provide further detail on proposals for stockholders, including amendments to stock plans, option repricing, preferred share and warrant share issuances, and a potential reverse stock split within an approved ratio range.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the key points of complex documents like 10-Ks, 10-Qs, 8-Ks, and proxy statements in plain language. Users can quickly see the main themes in Allurion’s disclosures on regulatory progress for the Allurion Smart Capsule, financial performance, risk factors, and governance decisions, while still having access to the full original SEC documents for deeper analysis.
Allurion Technologies, Inc. large shareholder RTW-affiliated entities filed an amended Schedule 13D to update their beneficial ownership of the company’s common stock.
RTW Investments, LP and Roderick Wong report beneficial ownership of 5,891,430 shares, representing 39.4% of Allurion’s common stock, with shared voting and dispositive power. RTW Master Fund, Ltd holds 3,138,798 shares (21.0%), and RTW Innovation Master Fund, Ltd holds 2,427,089 shares (16.2%), all on a shared basis.
The ownership percentages are calculated from shares outstanding reported in a January 2026 prospectus plus additional shares issued under an Inducement Offer to Exercise Common Stock Purchase Warrants that closed on February 26, 2026. The filing states that no transactions in Allurion securities were made by the reporting persons in the past sixty days and that the higher percentage figures reflect an increase in Allurion’s outstanding shares.
Allurion Technologies reported that the New York Stock Exchange plans to begin delisting proceedings because the company no longer meets the NYSE rule requiring at least $50 million in stockholders’ equity or a $50 million average market value. Allurion will appeal this determination to an NYSE board committee, and its common stock and warrants are expected to continue trading on the NYSE during the review period, provided it meets other listing requirements.
The company is pursuing several steps to regain compliance or qualify for listing on another exchange, including capital-raising efforts, negotiations with creditors and security holders, an agreement to exchange all outstanding debt for preferred stock at a premium to the current share price, and a recent warrant inducement transaction. Management warns that there is no assurance the appeal or these initiatives will succeed, and notes that any ultimate delisting could reduce liquidity, pressure the share price, limit access to public capital markets, and weaken its ability to grant equity incentives.
Allurion Technologies entered into a warrant exercise inducement agreement with certain existing warrant holders. The company cut the exercise price of its outstanding warrants to
In return, Allurion will issue new warrants to these holders to purchase up to 5,319,130 additional shares of common stock at
Allurion engaged Roth Capital Partners as financial advisor and will pay a fee equal to
Allurion Technologies reported that the U.S. Food and Drug Administration granted premarket approval for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, for adults aged 22–65 with obesity and a BMI between 30 and 40 kg/m2 after at least one unsuccessful weight-loss attempt.
The Smart Capsule is swallowed in a brief office visit, forms a gastric balloon that remains in the stomach for about four months, then empties and passes naturally, with the option for a second capsule within a 10‑month treatment period. Allurion estimates this indication provides access to roughly 80 million Americans within the approved BMI range.
The company highlights prior use of the Smart Capsule outside the United States in over 200,000 patients and cites published data showing around 14% total body weight loss with one balloon cycle and over 20% with two cycles or when combined with low‑dose GLP‑1 therapies. Allurion also notes risks around maintaining FDA approval, successful commercialization, and obtaining sufficient financing to continue as a going concern.
Allurion Technologies, Inc. has registered 5,988,024 shares of common stock for potential resale by existing securityholders. The shares include 2,994,012 shares issued in a November 2025 private placement and 2,994,012 shares issuable upon exercise of accompanying warrants with a $1.67 exercise price. The company will not receive proceeds from any resale of these shares but could receive up to approximately $5.0 million if all November 2025 warrants are exercised for cash. As of January 5, 2026, 12,279,181 shares of common stock were outstanding. The prospectus notes that large or sustained resales could put pressure on the stock price. Allurion remains an emerging growth and smaller reporting company and highlights recent financing steps and an exchange agreement with RTW tied to Series B preferred stock and specified performance conditions.
Allurion Technologies, Inc. furnished an update on its business by disclosing that it issued a press release with selected preliminary financial results for the quarter and year ended December 31, 2025. The company states that the full text of this press release is provided as Exhibit 99.1 and is incorporated by reference. The information about these preliminary results is being furnished under the rules governing current reports and is expressly described as not being "filed" for liability purposes under the Exchange Act.
Allurion Technologies, Inc. has filed a resale registration covering up to 5,988,024 shares of common stock that may be sold from time to time by existing investors. This total consists of 2,994,012 shares issued in a November 2025 private placement and 2,994,012 shares issuable upon exercise of accompanying November 2025 Private Placement Warrants. Allurion will not receive proceeds from investors’ resale of these shares, but could receive up to approximately $5.0 million if all of the warrants are exercised in cash at an exercise price of $1.67 per share. As of January 5, 2026, 12,279,181 shares of common stock were outstanding. The company highlights that large, ongoing resales under this prospectus could put pressure on its stock price. Allurion develops a weight-loss platform built around its swallowable, procedure-free intragastric balloon and a digital Virtual Care Suite.
Allurion Technologies, Inc. has filed a prospectus supplement updating its Form S-1 registration statement covering up to 65,211,325 shares of common stock. The supplement incorporates a recent current report that details the results of the company’s 2025 annual meeting of stockholders held on December 18, 2025, where seven proposals were presented for a vote. The company notes there were sufficient votes to approve Proposals 3 through 7, so a contingent proposal to adjourn the meeting for additional solicitation was not needed. Allurion’s common stock trades on the NYSE under the symbol ALUR, which last closed at $1.47 per share on December 19, 2025, while its public warrants closed at $0.02 per warrant.
Allurion Technologies, Inc. has a prospectus supplement covering up to 56,548,268 shares of common stock, updating its existing S-1/A prospectus with information from a recent Form 8-K. The update attaches the report on the company’s 2025 Annual Meeting of Stockholders held on December 18, 2025, where seven proposals were considered and approved without needing an adjournment. Stockholders elected directors including Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey, with several other proposals receiving strong support based on the reported vote totals.
The company’s common stock trades on the NYSE under the symbol ALUR, and its public warrants trade under ALUR.WS. On December 19, 2025, the common stock last traded at $1.47 per share and the public warrants at $0.02 per warrant. Allurion is classified as an emerging growth company, which allows it to follow reduced public reporting requirements, and it reminds investors to review the risk factors in the base prospectus before investing.